- Home
- REFI vs VNDA Comparison
REFI vs VNDA Comparison
Compare REFI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | VNDA |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 387.9M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | REFI | VNDA |
|---|---|---|
| Price | $11.27 | $6.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 131.2K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | $48,857,628.00 | ★ $216,105,000.00 |
| Revenue This Year | $17.47 | $21.35 |
| Revenue Next Year | $0.06 | $37.40 |
| P/E Ratio | $49.13 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $10.74 | $4.14 |
| 52 Week High | $14.62 | $9.91 |
Technical Indicators
Market Signals| Indicator | REFI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 39.38 |
| Support Level | $10.74 | $5.85 |
| Resistance Level | $11.54 | $6.73 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 46.08 | 8.61 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.